IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition

pharmafile | April 11, 2016 | News story | Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV 

German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally lower benefit in comparison with the competition, according to an early benefit assessment.

The regulator has said the drug offered minor added benefit for pre-treated women, but not for men.

The drug is indicated if the previous treatment has failed or cannot be continued due to side effects.

The Federal Joint Committee (G-BA) said between four groups of patients depending on age (adolescents/ adults) and previous treatment (pre-treated/ treatment-naive). Genvoya was compared with efavirenz in combination with two other drugs in treatment-naive patients, and with individual antiretroviral therapy in pre-treated patients.

US drug major Bristol-Myers Squibb (NYSE: BMY) markets efavirenz  under the brand name Sustiva in the US, the United Kingdom, Ireland, France, Germany, Italy, and Spain. 

Anjali Shukla

Related Content

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …

Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Latest content